Page last updated: 2024-12-08

tak 603

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TAK 603: potential anti-inflammatory agent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	153980
CHEMBL ID	439817
SCHEMBL ID	607272
MeSH ID	M0272736

Synonyms (20)

Synonym
ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1h-1,2,4-triazol-1-ylmethyl)-3-quinolinecarboxylate
CHEMBL439817
ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate
unii-w6rzk26fcb
w6rzk26fcb ,
3-quinolinecarboxylic acid, 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1h-1,2,4-triazol-1-ylmethyl)-, ethyl ester
158146-85-1
tak 603
tak-603
SCHEMBL607272
6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylic acid ethyl ester
CLQRMSBSMHXMMC-UHFFFAOYSA-N
6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-2-(1,2,4triazol-1-ylmethyl)quinoline-3-carboxylic acid ethyl ester
6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-2-(1,2,4-triazol- 1-ylmethyl)quinoline-3-carboxylic acid ethyl ester
ethyl 6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate
DTXSID30166380
Q27292404
AKOS040749609
HY-120049
CS-0069378

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
" The bioavailability of TAK-603 was 53% and 42% in rats and dogs, respectively."	( Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs. Kiyota, Y; Motohashi, M; Tagawa, Y; Tanayama, S; Yoshimura, Y, 1998)	0.3

Dosage Studied

Excerpt	Relevance	Reference
"The disposition of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl) quinoline-3-carboxylate (CAS 158146-85-1, TAK-603) after single oral dosing of 14C-labeled TAK-603 ([14C]TAK-603) at 10 mg/kg to rats and dogs was studied."	( Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs. Kiyota, Y; Motohashi, M; Tagawa, Y; Tanayama, S; Yoshimura, Y, 1998)	0.3

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay ID	Title	Year	Journal	Article
AID169313	Bone resorption inhibitory effect was evaluated as calcium released from bone into medium at 30 uM compound concentration, expressed as percent of control	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
AID176202	Effective dose to to inhibit the rat's left hand paw swelling by 50%.	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
AID184059	Inhibitory effect of 12.5 mg/Kg orally administered compound against swelling of right hand paw as a measure of anti-inflammatory activity	1996	Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26	Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	11 (68.75)	18.2507
2000's	5 (31.25)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.35 (24.57)
Research Supply Index	2.89 (2.92)
Research Growth Index	4.24 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.35)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (6.25%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (93.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	2	1	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	5.47	15	1	1,2,3-triazole
justicidin a justicidins: from Justica procumbens	1.99	1	0	lignan
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	1.99	1	0
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.99	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic

Condition	Relationship Strength	Studies	Trials
Adjuvant Arthritis [description not available]	3.24	6	0
Bone Loss, Osteoclastic [description not available]	2.4	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.39	2	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.99	1	0
Innate Inflammatory Response [description not available]	2.02	1	0
Besnier-Boeck Disease [description not available]	2.02	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.02	1	0
Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.	2.02	1	0
Bright Disease A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.	2.03	1	0
Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.	2.03	1	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.03	1	0
Graft-Versus-Host Disease [description not available]	2.42	2	0
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	2.42	2	0
Autoimmune Disease [description not available]	2.39	2	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	2.39	2	0
Allergic Encephalomyelitis [description not available]	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.38	1	1
Acute Disease Disease having a short and relatively severe course.	2	1	0

chemdatabank.com